Boston Scientific (BSX) said it now estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent on a reported basis and 6.5 to 8.0 percent on an organic basis. The company now estimates adjusted EPS, excluding certain items, of $3.34 to $3.41. The company previously estimated net sales growth to be approximately 10.5 to 11.5 percent on a reported basis and 10.0 to 11.0 percent on an organic basis, and adjusted EPS, excluding items, of $3.43 to $3.49.
The company estimates net sales growth for the second quarter of 2026 to be approximately 5.5 to 7.5 percent on a reported basis and 5.0 to 7.0 percent on an organic basis. The company estimates adjusted EPS, excluding certain items, of $0.82 to $0.84.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.